![](https://savarapharma.com/wp-content/uploads/page-header-blue-ridges-m.jpg)
![](https://savarapharma.com/wp-content/uploads/page-header-blue-ridges-d.jpg)
Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): | March 11, 2013 |
Mast Therapeutics, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
Delaware | 001-32157 | 84-1318182 |
_____________________ (State or other jurisdiction |
_____________ (Commission |
______________ (I.R.S. Employer |
of incorporation) | File Number) | Identification No.) |
12390 El Camino Real, Suite 150, San Diego, California | 92130 | |
_________________________________ (Address of principal executive offices) |
___________ (Zip Code) |
Registrants telephone number, including area code: | 858-552-0866 |
ADVENTRX Pharmaceuticals, Inc.
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On March 11, 2013, the registrant issued a press release announcing completion of its name change from ADVENTRX Pharmaceuticals, Inc. to Mast Therapeutics, Inc. as of that date. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The list of exhibits called for by this Item is incorporated by reference to the Exhibit Index filed with this report.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Mast Therapeutics, Inc. | ||||
March 12, 2013 | By: |
/s/ Patrick L. Keran
|
||
|
||||
Name: Patrick L. Keran | ||||
Title: President and Chief Operating Officer |
Exhibit Index
Exhibit No. | Description | |
|
|
|
99.1
|
Press release, dated March 11, 2013 |
ADVENTRX COMPLETES NAME CHANGE TO
MAST THERAPEUTICS, INC.; NEW TICKER SYMBOL: MSTX
SAN DIEGO March 11, 2013 ADVENTRX Pharmaceuticals, Inc. today completed its previously announced corporate name change to Mast Therapeutics, Inc. In addition, effective at the opening of trading today, the Companys new ticker symbol is MSTX. The Companys common stock is listed on the NYSE MKT.
The corporate website is available at www.masttherapeutics.com.
The Companys lead product candidate will be referred to as MST-188 (formerly, ANX-188).
A new CUSIP number of 576314 108 has been assigned to the Companys common stock and a new CUSIP number of 576314 116 has been assigned to the common stock purchase warrants of the Company that were issued in November 2011.
Outstanding stock certificates and warrants for shares of the Companys common stock are not affected by the name change; they will continue to be valid and need not be exchanged.
About Mast Therapeutics
Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in San Diego,
CA. The Company is leveraging the MAST (Molecular Adhesion and Sealant Technology) platform,
derived from over two decades of clinical, nonclinical and manufacturing experience with purified
and non-purified poloxamers, to develop MST-188, its lead product candidate, for serious or
life-threatening diseases with significant unmet needs. MST-188 is a cytoprotective,
hemorheologic, anti-inflammatory and anti-thrombotic agent that has potential utility in diseases
or conditions characterized by microcirculatory insufficiency (endothelial dysfunction and/or
impaired blood flow).
The Company is recruiting subjects in EPIC, a pivotal phase 3 study of MST-188 in sickle cell disease. The Company plans to initiate a phase 2 clinical study of MST-188 in acute limb ischemia, a complication of peripheral arterial disease, in late 2013 or early 2014. More information can be found on the Companys web site at www.masttherapeutics.com.
Forward Looking Statements
Mast Therapeutics cautions you that statements included in this press release that are not a
description of historical facts are forward-looking statements that are based on the Companys
current expectations and assumptions. Such forward-looking statements include, but are not limited
to, statements regarding the Companys development plans for MST-188, including in sickle cell
disease and acute limb ischemia, and the timing of activities related to those plans. Among the
factors that could cause or contribute to material differences between the Companys actual results
and the expectations indicated by the forward-looking statements are risks and uncertainties that
include, but are not limited to: the potential for delays in the commencement or completion of
clinical studies, including as a result of difficulties in obtaining regulatory agency agreement on
clinical development plans or clinical study design, opening trial sites, enrolling study subjects,
manufacturing clinical trial material, completing manufacturing process development activities, and
being subject to a clinical hold; the risk of suspension or termination of a clinical study,
including due to lack of adequate funding or patient safety concerns; the potential for
institutional review boards or the FDA or other regulatory agencies to require additional
nonclinical or clinical studies prior to initiation of planned phase 2 clinical studies of MST-188
in any particular indication in which the Company determines to develop MST-188, including acute
limb ischemia, which likely would increase the total time and cost of development in the
indication; the risk that clinical studies of MST-188 are not successfully executed and/or do not
successfully demonstrate its safety or efficacy; the risk that, even if clinical studies are
successful, the FDA determines they are not sufficient to support a new drug application; the risk
that even if clinical studies of MST-188 in one indication are successful, clinical studies in
another indication may not be successful; the Companys reliance on contract research organizations
(CROs), contract manufacturing organizations (CMOs), and other third parties to assist in the
conduct of important aspects of development of MST-188, including clinical studies, and regulatory
activities for MST-188 and that such third parties may fail to perform as expected; the Companys
ability to obtain additional funding on a timely basis or on acceptable terms, or at all; the
potential for the Company to delay, reduce or discontinue current and/or planned development
activities, including clinical studies, partner MST-188 at inopportune times or pursue less
expensive but higher-risk development paths if it is unable to raise sufficient additional capital
as needed; the risk that acceptable partnering opportunities for MST-188 may not be available in
particular jurisdictions or indications and, consequently, the Company may not be able to pursue
development of MST-188 in certain jurisdictions and indications; the risk that the FDA does not
grant marketing approval of MST-188, on a timely basis, or at all; the risk that the Company is not
able to adequately protect its intellectual property rights relating to the MAST platform and
MST-188 and prevent competitors from duplicating or developing equivalent versions of its product
candidates, including MST-188; and other risks and uncertainties more fully described in the
Companys press releases and periodic filings with the Securities and Exchange Commission. The
Companys public filings with the Securities and Exchange Commission are available at www.sec.gov.
You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. Mast Therapeutics does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date hereof, except as may be required by law.
Contact: |
Mast Therapeutics Ioana C. Hone (ir@mastthera.com) |
858-552-0866 Ext. 303 |
# # #